Pertuzumab and Trastuzumab hyaluronidase (Phesgo)
(Redirected from Pertuzumab & Trastuzumab hyaluronidase (Phesgo))
Jump to navigation
Jump to search
General information
A combination of pertuzumab and trastuzumab, to be given by subcutaneous injection
Diseases for which it is established
History of changes in FDA indication
- 2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)
- 2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. (Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)
- 2020-06-29: Initial approval in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Based on CLEOPATRA & FeDeriCa)
History of changes in EMA indication
- 2020-12-21: Initial authorization
Also known as
- Generic name: pertuzumab/trastuzumab/hyaluronidase-zzxf
- Brand name: Phesgo